{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-088051","form_type":"8-K","ticker":"CYPH","cik":"0001509745","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.310600+00:00","generated_at":"2026-05-31T10:01:34.769560+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Leap Therapeutics Q2 net loss $20.4M; DKN-01 ORR 33% in CRC; $40M PIPE completed","bullets":["Net loss of $20.4M in Q2 2024 vs $13.4M in Q2 2023; R&D expenses rose to $17.9M on trial costs.","DKN-01 combo achieved 33% ORR (38% left-sided) in Part A of DeFianCe CRC study; median PFS 6.3 months.","Enrollment in Part B expanded to 180 patients; completion expected Sept 2024, data mid-2025.","DisTinGuish Part C gastric/GEJ cancer data expected Q4 2024 or early 2025.","Completed $40M private placement with Gilead, Samsara, others; cash $78.5M funds into Q2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-088051","json":"https://secwatch.observer/filing/0001104659-24-088051.json","markdown":"https://secwatch.observer/filing/0001104659-24-088051.md","text":"https://secwatch.observer/filing/0001104659-24-088051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509745/000110465924088051/0001104659-24-088051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509745/000110465924088051/tm2421304d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:01:34.769560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}